CHERAMY-BIEN, Jean-Paul ; Centre Hospitalier Universitaire de Liège - CHU > Service de chirurgie cardio-vasculaire et thoracique
Purnelle, Audrey
Pirotte, Bernard ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Dogné, Jean-Michel
Hanson, Julien ; Université de Liège - ULiège > Département de pharmacie > Chimie pharmaceutique
Defraigne, Jean-Olivier ; Université de Liège - ULiège > Département des sciences cliniques > Chirurgie cardio-vasculaire et thoracique
Drion, Pierre ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > GIGA-R:Méth. expér.des anim. de labo et éth. en expér. anim.
SAKALIHASAN, Natzi ; Centre Hospitalier Universitaire de Liège - CHU > Service de chirurgie cardio-vasculaire et thoracique
Language :
English
Title :
Therapeutic Applications of Prostaglandins and Thromboxane A2 Inhibitors in Abdominal Aortic Aneurysms
Nchimi A, Courtois A, El Hachemi M, et al. Multimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model. Euro Radiol 2016; 26(7): 2378-86.
Michel JB, Martin-Ventura JL, Egido J, et al. Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans. Cardiovasc Res 2011; 90(1): 18-27.
Behr-Rasmussen C, Grondal N, Bramsen MB, Thomsen MD, Lindholt JS. Mural thrombus and the progression of abdominal aortic aneurysms: A large population-based prospective cohort study. Euro J Vasc Endovasc Surg 2014; 48(3): 301-7.
Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res 2009; 50 Suppl: S423-8.
Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31(5): 986-1000.
Tong J, Holzapfel GA. Structure, mechanics, and histology of intraluminal thrombi in abdominal aortic aneurysms. Ann Biomed Eng 2015; 43(7): 1488-501.
Wilson JS, Virag L, Di Achille P, Karsaj I, Humphrey JD. Bio-chemomechanics of intraluminal thrombus in abdominal aortic aneurysms. J Biomech Eng 2013; 135(2): 021011.
Lindholt JS, Bjorck M, Michel JB. Anti-platelet treatment of mid-dle-sized abdominal aortic aneurysms. Curr Vasc Pharmacol 2013; 11(3): 305-13.
Kazi M, Thyberg J, Religa P, et al. Influence of intraluminal thrombus on structural and cellular composition of abdominal aortic aneurysm wall. J Vasc Surg 2003; 38(6): 1283-92.
Touat Z, Ollivier V, Dai J, et al. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol 2006; 168(3): 1022-30.
Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 2009; 102(2): 248-57.
Montalescot G. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease. Clin Appl Thromb Hemost 2011; 17(4): 371-80.
Moll FL, Powell JT, Fraedrich G, et al. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. Eur J Vasc Endovasc Surg 2011; 41 (Suppl 1): S1-S58.
Dai J, Louedec L, Philippe M, Michel JB, Houard X. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. J Vasc Surg 2009; 49(3): 719-27.
Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41: 661-90.
Lewis RA, Soter NA, Diamond PT, et al. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982; 129(4): 1627-31.
Sugimoto Y, Yamasaki A, Segi E, et al. Failure of parturition in mice lacking the prostaglandin F receptor. Science 1997; 277(5326): 681-3.
Gomez I, Foudi N, Longrois D, Norel X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot Essent Fatty Acids 2013; 89(2-3): 55-63.
Friedman EA, Ogletree ML, Haddad EV, Boutaud O. Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease. Thromb Res 2015; 136(3): 493-503.
Babaev VR, Chew JD, Ding L, et al. Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis. Cell Metab 2008; 8(6): 492-501.
Linton MF, Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 2004; 4(2): 116-23.
Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther 2008; 118(2): 161-80.
Raval M, Frank PG, Laury-Kleintop L, Yan G, Lanza-Jacoby S. Celecoxib combined with atorvastatin prevents progression of atherosclerosis. J Surg Res 2010; 163(2): e113-22.
Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364(9450): 2021-9.
Schror K, Bretschneider E, Fischer K, et al. Thrombin receptors in vascular smooth muscle cells-function and regulation by vasodila-tory prostaglandins. Thromb Haemost 2010; 103(5): 884-90.
Feletou M, Vanhoutte PM, Verbeuren TJ. The thromboxane/endoperoxide receptor (TP): The common villain. J Cardiovasc Pharmacol 2010; 55(4): 317-32.
Giannarelli C, Zafar MU, Badimon JJ. Prostanoid and TP-receptors in atherothrombosis: Is there a role for their antagonism? Thromb and Haemost 2010; 104(5): 949-54.
Capra V, Back M, Angiolillo DJ, Cattaneo M, Sakariassen KS. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014; 12(2): 126-37.
Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther 2008; 118(1): 18-35.
Fitzgerald DJ, Doran J, Jackson E, FitzGerald GA. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986; 77(2): 496-502.
Grad E, Pachino RM, FitzGerald GA, Danenberg HD. Role of thromboxane receptor in C-reactive protein-induced thrombosis. Arterioscler Thromb Vasc Biol 2012; 32(10): 2468-74.
Thomas DW, Mannon RB, Mannon PJ, et al. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J Clin Invest 1998; 102(11): 1994-2001.
Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114(6): 784-94.
Cherdon C, Rolin S, Hanson J, et al. BM-573 inhibits the development of early atherosclerotic lesions in Apo E deficient mice by blocking TP receptors and thromboxane synthase. Prostaglandins Other Lipid Mediat 2011; 94(3-4): 124-32.
Guzik TJ, Sadowski J, Kapelak B, et al. Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins. Arterioscler Thromb Vasc Biol 2004; 24(9): 1614-20.
Seno T, Inoue N, Gao D, et al. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb Res 2001; 103(5): 399-409.
Milne GL, Yin H, Brooks JD, et al. Quantification of F2-isoprostanes in biological fluids and tissues as a measure of oxidant stress. Methods Enzymol 2007; 433: 113-26.
De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo. Thromb Haemost 1989; 61(1): 43-9.
Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT). Circulation 1994; 89(2): 588-95.
Ghuysen A, Dogne JM, Chiap P, et al. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc Drug Rev 2005; 23(1): 1-14.
Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997; 25(5): 810-5.
Eagleton MJ. Inflammation in abdominal aortic aneurysms: cellular infiltrate and cytokine profiles. Vascular 2012; 20(5): 278-83.
Walton LJ, Franklin IJ, Bayston T, et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999; 100(1): 48-54.
Cheuk BL, Cheng SW. Differential secretion of prostaglandin E(2), thromboxane A(2) and interleukin-6 in intact and ruptured abdominal aortic aneurysms. Int J Mol Med 2007; 20(3): 391-5.
Corcoran ML, Stetler-Stevenson WG, Brown PD, Wahl LM. Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem 1992; 267(1): 515-9.
Bayston T, Ramessur S, Reise J, Jones KG, Powell JT. Prostaglandin E2 receptors in abdominal aortic aneurysm and human aortic smooth muscle cells. J Vasc Surg 2003; 38(2): 354-9.
Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase. J Vasc Surg 1999; 29(5): 884-92; discussion 92-3.
Holmes DR, Petrinec D, Wester W, Thompson RW, Reilly JM. Indomethacin prevents elastase-induced abdominal aortic aneurysms in the rat. J Surg Res 1996; 63(1): 305-9.
Armstrong PJ, Franklin DP, Carey DJ, Elmore JR. Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors. Ann Vasc Surg 2005; 19(2): 248-57.
Ghoshal S, Loftin CD. Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. PLoS One 2012; 7(11): e44369.
King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006; 26(5): 1137-43.
Mukherjee K, Gitlin JM, Loftin CD. Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype. J Cardiovasc Pharmacol 2012; 60(6): 520-9.
Keeling WB, Hackmann AE, Colter ME, et al. MF-tricyclic inhibits growth of experimental abdominal aortic aneurysms. J Surg Res 2007; 141(2): 192-5.
Cao RY, St Amand T, Li X, et al. Prostaglandin receptor EP4 in abdominal aortic aneurysms. Am J Pathol 2012; 181(1): 313-21.
Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 2007; 73(1): 227-36.
Owens AP, 3rd, Edwards TL, Antoniak S, et al. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2015; 35(9): 2032-41.
Wang M, Lee E, Song W, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 2008; 117(10): 1302-9.
Yokoyama U, Ishiwata R, Jin MH, et al. Inhibition of EP4 signaling attenuates aortic aneurysm formation. PLoS One 2012; 7(5): e36724.
Tang EH, Shvartz E, Shimizu K, et al. Deletion of EP4 on bone marrow-derived cells enhances inflammation and angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2011; 31(2): 261-9.
Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975; 72(8): 3073-6.
Lindholt JS, Sorensen HT, Michel JB, Thomsen HF, Henneberg EW. Low-dose aspirin may prevent growth and later surgical repair of medium-sized abdominal aortic aneurysms. Vasc Endovasc Surg 2008; 42(4): 329-34.
Thompson A, Cooper JA, Fabricius M, et al. An analysis of drug modulation of abdominal aortic aneurysm growth through 25 years of surveillance. J Vasc Surg 2010; 52(1): 55-61 e2.
Karlsson L, Gnarpe J, Bergqvist D, Lindback J, Parsson H. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms--a prospective randomized double-blind trial. J Vasc Surg 2009; 50(1): 23-9.
Sweeting MJ, Thompson SG, Brown LC, Powell JT, collaborators R. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg 2012; 99(5): 655-65.
Ferguson CD, Clancy P, Bourke B, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010; 159(2): 307-13.
Bailey MA, Aggarwal R, Bridge KI, et al. Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. J Thromb Haemost 2015; 13(5): 795-801.
Wemmelund H, Jorgensen TM, Hogh A, et al. Low-dose aspirin and rupture of abdominal aortic aneurysm. J Vasc Surg 2017; 65(3): 616-25 e4.
Cheuk BL, Cheng SW. Can local secretion of prostaglandin E2, thromboxane B2, and interleukin-6 play a role in ruptured abdominal aortic aneurysm? World J Surg 2008; 32(1): 55-61.
Huang RY, Li MY, Ng CS, et al. Thromboxane A2 receptor alpha promotes tumor growth through an autoregulatory feedback pathway. J Mol Cell Biol 2013; 5(6): 380-90.
Reilly JM. Plasminogen activators in abdominal aortic aneurysmal disease. Ann N Y Acad Sci 1996; 800: 151-6.
Defawe OD, Colige A, Lambert CA, et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res 2003; 60(1): 205-13.
Courtois A, Nusgens BV, Hustinx R, et al. 18F-FDG uptake assessed by PET/CT in abdominal aortic aneurysms is associated with cellular and molecular alterations prefacing wall deterioration and rupture. J Nucl Med 2013; 54(10): 1740-7.
Cooper TW, Eisen AZ, Stricklin GP, Welgus HG. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci USA 1985; 82(9): 2779-83.
Khan JA, Abdul Rahman MN, Mazari FA, et al. Intraluminal thrombus has a selective influence on matrix metalloproteinases and their inhibitors (tissue inhibitors of matrix metalloproteinases) in the wall of abdominal aortic aneurysms. Anna Vasc Surg 2012; 26(3): 322-9.
